Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-28T03:58:44.143Z Has data issue: false hasContentIssue false

Fetal Growth and Well-being

from Section 2: - Fetal Disease: Pathogenesis and Treatment

Published online by Cambridge University Press:  21 October 2019

Edited by
Mark D. Kilby ,
Anthony Johnson  and
Dick Oepkes
Mark D. Kilby
Affiliation:
University of Birmingham
Anthony Johnson
Affiliation:
University of Texas Medical School at Houston
Dick Oepkes
Affiliation:
Leids Universitair Medisch Centrum
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Fetal Therapy
Scientific Basis and Critical Appraisal of Clinical Benefits
 , pp. 248 - 301
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Boers, KE, Vijgen, SM, Bijlenga, D, van der Post, JA, Bekedam, DJ, Kwee, A, et al. Induction versus expectant monitoring for intrauterine growth restriction at term: randomised equivalence trial (DIGITAT). BMJ. 2010; 341: c7087.CrossRefGoogle ScholarPubMed
Audette, MC, Kingdom, JC. Screening for fetal growth restriction and placental insufficiency. Semin Fetal Neonatal Med. 2018; 23: 119–25.Google Scholar
Gaccioli, F, Aye, I, Sovio, U, Charnock-Jones, DS, Smith, GCS. Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. Am J Obstet Gynecol. 2018; 218: S725–37.CrossRefGoogle ScholarPubMed
Kingdom, JC, Audette, MC, Hobson, SR, Windrim, RC, Morgen, E. A placenta clinic approach to the diagnosis and management of fetal growth restriction. Am J Obstet Gynecol. 2018; 218: S803–17.Google Scholar
Jackson, MR, Walsh, AJ, Morrow, RJ, Mullen, JB, Lye, SJ, Ritchie, JW. Reduced placental villous tree elaboration in small-for-gestational-age pregnancies: relationship with umbilical artery Doppler waveforms. Am J Obstet Gynecol. 1995; 172: 518–25.CrossRefGoogle ScholarPubMed
Robson, SC, Simpson, H, Ball, E, Lyall, F, Bulmer, JN. Punch biopsy of the human placental bed. Am J Obstet Gynecol. 2002; 187: 1349–55.CrossRefGoogle ScholarPubMed
Burton, GJ. Oxygen, the Janus gas; its effects on human placental development and function. J Anat. 2009; 215: 27–35.Google Scholar
Burton, GJ, Watson, AL, Hempstock, J, Skepper, JN, Jauniaux, E. Uterine glands provide histiotrophic nutrition for the human fetus during the first trimester of pregnancy. J Clin Endocrinol Metab. 2002; 87: 2954–9.Google Scholar
Burton, GJ, Jauniaux, E, Watson, AL. Maternal arterial connections to the placental intervillous space during the first trimester of human pregnancy: the Boyd collection revisited. Am J Obstet Gynecol. 1999; 181: 718–24.Google Scholar
Burton, GJ, Hempstock, J, Jauniaux, E. Oxygen, early embryonic metabolism and free radical-mediated embryopathies. Reprod Biomed Online. 2003; 6: 84–96.CrossRefGoogle ScholarPubMed
Jauniaux, E, Hempstock, J, Greenwold, N, Burton, GJ. Trophoblastic oxidative stress in relation to temporal and regional differences in maternal placental blood flow in normal and abnormal early pregnancies. Am J Pathol. 2003; 162: 115–25.Google Scholar
Kaufmann, P, Black, S, Huppertz, B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod. 2003; 69: 1–7.CrossRefGoogle ScholarPubMed
Burton, GJ, Jauniaux, E, Charnock-Jones, DS. The influence of the intrauterine environment on human placental development. Int J Dev Biol. 2010; 54: 303–12.CrossRefGoogle ScholarPubMed
Nordenvall, M, Ullberg, U, Laurin, J, Lingman, G, Sandstedt, B, Ulmsten, U. Placental morphology in relation to umbilical artery blood velocity waveforms. Eur J Obstet Gynecol Reprod Biol. 1991; 40: 179–90.CrossRefGoogle ScholarPubMed
Proctor, LK, Toal, M, Keating, S, Chitayat, D, Okun, N, Windrim, RC, et al. Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. 2009; 34: 274–82.Google Scholar
Wright, E, Audette, MC, Ye, XY, Keating, S, Hoffman, B, Lye, SJ, et al. Maternal vascular malperfusion and adverse perinatal outcomes in low-risk nulliparous women. Obstet Gynecol. 2017; 130: 1112–20.Google Scholar
Dunk, C, Smith, S, Hazan, A, Whittle, W, Jones, RL. Promotion of angiogenesis by human endometrial lymphocytes. Immunol Invest. 2008; 37: 583–610.CrossRefGoogle ScholarPubMed
Kadyrov, M, Kingdom, JC, Huppertz, B. Divergent trophoblast invasion and apoptosis in placental bed spiral arteries from pregnancies complicated by maternal anemia and early-onset preeclampsia/intrauterine growth restriction. Am J Obstet Gynecol. 2006; 194: 557–63.CrossRefGoogle ScholarPubMed
Burton, GJ, Woods, AW, Jauniaux, E, Kingdom, JC. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta. 2009; 30: 473–82.Google Scholar
Nanaev, A, Chwalisz, K, Frank, HG, Kohnen, G, Hegele-Hartung, C, Kaufmann, P. Physiological dilation of uteroplacental arteries in the guinea pig depends on nitric oxide synthase activity of extravillous trophoblast. Cell Tissue Res. 1995; 282: 407–21.Google Scholar
Lyall, F, Barber, A, Myatt, L, Bulmer, JN, Robson, SC. Hemeoxygenase expression in human placenta and placental bed implies a role in regulation of trophoblast invasion and placental function. Faseb J. 2000; 14: 208–19.Google Scholar
Kaufmann, P, Mayhew, TM, Charnock-Jones, DS. Aspects of human fetoplacental vasculogenesis and angiogenesis. II. Changes during normal pregnancy. Placenta. 2004; 25: 114–26.Google Scholar
Simmons, DG, Natale, DR, Begay, V, Hughes, M, Leutz, A, Cross, JC. Early patterning of the chorion leads to the trilaminar trophoblast cell structure in the placental labyrinth. Development. 2008; 135: 2083–91.Google Scholar
Simpson, RA, Mayhew, TM, Barnes, PR. From 13 weeks to term, the trophoblast of human placenta grows by the continuous recruitment of new proliferative units: a study of nuclear number using the disector. Placenta. 1992; 13: 501–12.Google Scholar
Baczyk, D, Drewlo, S, Proctor, L, Dunk, C, Lye, S, Kingdom, J. Glial cell missing-1 transcription factor is required for the differentiation of the human trophoblast. Cell Death Differ. 2009; 16: 719–27.Google Scholar
Liang, CY, Wang, LJ, Chen, CP, Chen, LF, Chen, YH, Chen, H. GCM1 regulation of the expression of syncytin 2 and its cognate receptor MFSD2A in human placenta. Biol Reprod. 2010; 83: 387–95.Google Scholar
Baczyk, D, Kibschull, M, Mellstrom, B, Levytska, K, Rivas, M, Drewlo, S, et al. DREAM mediated regulation of GCM1 in the human placental trophoblast. PLoS ONE. 2013; 8: e51837.Google Scholar
Kingdom, JC, Drewlo, S. Is heparin a placental anticoagulant in high-risk pregnancies? Blood. 2011; 118: 4780–8.Google Scholar
Tanaka, S, Kunath, T, Hadjantonakis, AK, Nagy, A, Rossant, J. Promotion of trophoblast stem cell proliferation by FGF4. Science. 1998; 282: 2072–5.Google Scholar
Baczyk, D, Dunk, C, Huppertz, B, Maxwell, C, Reister, F, Giannoulias, D, et al. Bi-potential behaviour of cytotrophoblasts in first trimester chorionic villi. Placenta. 2006; 27: 367–74.Google Scholar
Nosi, U, Lanner, F, Huang, T, Cox, B. Overexpression of trophoblast stem cell-enriched microRNAs promotes trophoblast fate in embryonic stem cells. Cell Rep. 2017; 19: 1101–9.Google Scholar
Macara, L, Kingdom, JC, Kaufmann, P, Kohnen, G, Hair, J, More, IA, et al. Structural analysis of placental terminal villi from growth-restricted pregnancies with abnormal umbilical artery Doppler waveforms. Placenta. 1996; 17: 37–48.Google Scholar
Huppertz, B, Frank, HG, Kingdom, JC, Reister, F, Kaufmann, P. Villous cytotrophoblast regulation of the syncytial apoptotic cascade in the human placenta. Histochem Cell Biol. 1998; 110: 495–508.CrossRefGoogle ScholarPubMed
Ellery, PM, Cindrova-Davies, T, Jauniaux, E, Ferguson-Smith, AC, Burton, GJ. Evidence for transcriptional activity in the syncytiotrophoblast of the human placenta. Placenta. 2009; 30: 329–34.Google Scholar
Fogarty, NM, Mayhew, TM, Ferguson-Smith, AC, Burton, GJ. A quantitative analysis of transcriptionally active syncytiotrophoblast nuclei across human gestation. J Anat. 2011; 219: 601–10.Google Scholar
Rajakumar, A, Cerdeira, AS, Rana, S, Zsengeller, Z, Edmunds, L, Jeyabalan, A, et al. Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension. 2012; 59: 256–64.Google Scholar
Burton, GJ, Jones, CJ. Syncytial knots, sprouts, apoptosis, and trophoblast deportation from the human placenta. Taiwan J Obstet Gynecol. 2009; 48: 28–37.Google Scholar
Parham, P, Guethlein, LA. Pregnancy immunogenetics: NK cell education in the womb? J Clin Invest. 2010; 120: 3801–4.Google Scholar
Munn, DH, Zhou, M, Attwood, JT, Bondarev, I, Conway, SJ, Marshall, B, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998; 281: 1191–3.Google Scholar
Walker, MG, Fitzgerald, B, Keating, S, Ray, JG, Windrim, R, Kingdom, JCP. Sex-specific basis of severe placental dysfunction leading to extreme preterm delivery. Placenta. 2011; 33: 568–71.Google Scholar
Saraswat, L, Bhattacharya, S, Maheshwari, A. Maternal and perinatal outcome in women with threatened miscarriage in the first trimester: a systematic review. BJOG. 2010; 117: 245–57.Google Scholar
Porat, S, Fitzgerald, B, Wright, E, Keating, S, Kingdom, JC. Placental hyperinflation and the risk of adverse perinatal outcome. Ultrasound Obstet Gynecol. 2013; 42: 315–21.Google Scholar
Fitzgerald, B, Shannon, P, Kingdom, J, Keating, S. Rounded intraplacental haematomas due to decidual vasculopathy have a distinctive morphology. J Clin Pathol. 2011; 64: 729–32.Google Scholar
Korzeniewski, SJ, Romero, R, Chaiworapongsa, T, Chaemsaithong, P, Kim, CJ, Kim, YM, et al. Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study. Am J Obstet Gynecol. 2016; 214: 629. e1–e17.Google Scholar
Walker, MG, Fitzgerald, B, Keating, S, Ray, JG, Windrim, R, Kingdom, JC. Sex-specific basis of severe placental dysfunction leading to extreme preterm delivery. Placenta. 2012; 33: 568–71.CrossRefGoogle ScholarPubMed
Krebs, C, Macara, LM, Leiser, R, Bowman, AW, Greer, IA, Kingdom, JC. Intrauterine growth restriction with absent end-diastolic flow velocity in the umbilical artery is associated with maldevelopment of the placental terminal villous tree. Am J Obstet Gynecol. 1996; 175: 1534–42.Google Scholar
Fitzgerald, B, Levytska, K, Kingdom, J, Walker, M, Baczyk, D, Keating, S. Villous trophoblast abnormalities in extremely preterm deliveries with elevated second trimester maternal serum hCG or inhibin-A. Placenta. 2011; 32: 339–45.CrossRefGoogle ScholarPubMed
Yung, HW, Calabrese, S, Hynx, D, Hemmings, BA, Cetin, I, Charnock-Jones, DS, et al. Evidence of placental translation inhibition and endoplasmic reticulum stress in the etiology of human intrauterine growth restriction. Am J Pathol. 2008; 173: 451–62.Google Scholar
Sharp, AN, Heazell, AE, Baczyk, D, Dunk, CE, Lacey, HA, Jones, CJ, et al. Preeclampsia is associated with alterations in the p53-pathway in villous trophoblast. PLoS ONE. 2014; 9: e87621.CrossRefGoogle ScholarPubMed
Ray, JE, Garcia, J, Jurisicova, A, Caniggia, I. Mtd/Bok takes a swing: proapoptotic Mtd/Bok regulates trophoblast cell proliferation during human placental development and in preeclampsia. Cell Death Differ. 2010; 17: 846–59.Google Scholar
Baczyk, D, Audette, MC, Coyaud, E, Raught, B, Kingdom, JC. Spatiotemporal distribution of small ubiquitin-like modifiers during human placental development and in response to oxidative and inflammatory stress. J Physiol. 2018; 596: 1587–600.Google Scholar
Drewlo, S, Levytska, K, Sobel, M, Baczyk, D, Lye, SJ, Kingdom, JC. Heparin promotes soluble VEGF receptor expression in human placental villi to impair endothelial VEGF signaling. J Thromb Haemost. 2011; 9: 2486–97.Google Scholar
Nevo, O, Soleymanlou, N, Wu, Y, Xu, J, Kingdom, J, Many, A, et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol. 2006; 291: R1085–93.CrossRefGoogle ScholarPubMed
Tache, V, LaCoursiere, DY, Saleemuddin, A, Parast, MM. Placental expression of vascular endothelial growth factor receptor-1/soluble vascular endothelial growth factor receptor-1 correlates with severity of clinical preeclampsia and villous hypermaturity. Hum Pathol. 2011; 42: 1283–8.CrossRefGoogle ScholarPubMed
Buhimschi, IA, Nayeri, UA, Zhao, G, Shook, LL, Pensalfini, A, Funai, EF, et al. Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. Sci Transl Med. 2014; 6: 245ra92.Google Scholar
Zeisler, H, Llurba, E, Chantraine, F, Vatish, M, Staff, AC, Sennstrom, M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016; 374: 13–22.Google Scholar
Griffin, M, Seed, PT, Duckworth, S, North, R, Myers, J, Mackillop, L, et al. Predicting delivery of a small-for-gestational-age infant and adverse perinatal outcome in women with suspected pre-eclampsia. Ultrasound Obstet Gynecol. 2018; 51: 387–95.CrossRefGoogle ScholarPubMed
Franco, C, Walker, M, Robertson, J, Fitzgerald, B, Keating, S, McLeod, A, et al. Placental infarction and thrombophilia. Obstet Gynecol. 2011; 117: 929–34.Google Scholar
Viero, S, Chaddha, V, Alkazaleh, F, Simchen, MJ, Malik, A, Kelly, E, et al. Prognostic value of placental ultrasound in pregnancies complicated by absent end-diastolic flow velocity in the umbilical arteries. Placenta. 2004; 25: 735–41.Google Scholar
Proctor, LK, Whittle, WL, Keating, S, Viero, S, Kingdom, JC. Pathologic basis of echogenic cystic lesions in the human placenta: role of ultrasound-guided wire localization. Placenta. 2010; 31: 1111–15.Google Scholar
Walker, M, Whittle, W, Keating, S, Kingdom, J. Sonographic diagnosis of chronic abruption. J Obstet Gynaecol Can. 2010; 32: 1056–8.CrossRefGoogle ScholarPubMed
D’Souza, R, Keating, S, Walker, M, Drewlo, S, Kingdom, J. Unfractionated heparin and placental pathology in high-risk pregnancies: secondary analysis of a pilot randomized controlled trial. Placenta. 2014; 35: 816–23.Google Scholar
Rolnik, DL, Wright, D, Poon, LC, O’Gorman, N, Syngelaki, A, de Paco Matallana, C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017; 377: 613–22.CrossRefGoogle ScholarPubMed
Figueras, F, Caradeux, J, Crispi, F, Eixarch, E, Peguero, A, Gratacos, E. Diagnosis and surveillance of late-onset fetal growth restriction. Am J Obstet Gynecol. 2018; 218: S790–802. e1.Google Scholar
Ting, JY, Kingdom, JC, Shah, PS. Antenatal glucocorticoids, magnesium sulfate, and mode of birth in preterm fetal small for gestational age. Am J Obstet Gynecol. 2018; 218: S818–28.Google Scholar
Nicolaides, KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn. 2011; 31: 7–15.Google Scholar
Dugoff, L. First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Obstet Gynecol. 2010; 115: 1052–61.Google Scholar
Smith, GC, Crossley, JA, Aitken, DA, Pell, JP, Cameron, AD, Connor, JM, et al. First-trimester placentation and the risk of antepartum stillbirth. JAMA. 2004; 292: 2249–54.Google Scholar
Smith, GC, Shah, I, Crossley, JA, Aitken, DA, Pell, JP, Nelson, SM, et al. Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol. 2006; 107: 161–6.Google Scholar
Crovetto, F, Triunfo, S, Crispi, F, Rodriguez-Sureda, V, Roma, E, Dominguez, C, et al. First-trimester screening with specific algorithms for early- and late-onset fetal growth restriction. Ultrasound Obstet Gynecol. 2016; 48: 340–8.Google Scholar
Rizzo, G, Capponi, A, Pietrolucci, ME, Capece, A, Arduini, D. First-trimester placental volume and vascularization measured by 3-dimensional power Doppler sonography in pregnancies with low serum pregnancy-associated plasma protein a levels. J Ultrasound Med. 2009; 28: 1615–22.Google Scholar
Yigiter, AB, Kavak, ZN, Durukan, B, Isci, H, Uzuner, A, Uyar, E, et al. Placental volume and vascularization flow indices by 3D power Doppler US using VOCAL technique and correlation with IGF-1, free beta-hCG, PAPP-A, and uterine artery Doppler at 11-14 weeks of pregnancy. J Perinat Med. 2011; 39: 137–41.Google Scholar
Alanjari, A, Wright, E, Keating, S, Ryan, G, Kingdom, J. Prenatal diagnosis, clinical outcomes, and associated pathology in pregnancies complicated by massive subchorionic thrombohematoma (Breus’ mole). Prenat Diagn. 2013; 33: 973–8.Google Scholar
Saleemuddin, A, Tantbirojn, P, Sirois, K, Crum, CP, Boyd, TK, Tworoger, S, et al. Obstetric and perinatal complications in placentas with fetal thrombotic vasculopathy. Pediatr Dev Pathol. 2010; 13: 459–64.Google Scholar
Salafia, CM, Pezzullo, JC, Minior, VK, Divon, MY. Placental pathology of absent and reversed end-diastolic flow in growth-restricted fetuses. Obstet Gynecol. 1997; 90: 830–6.CrossRefGoogle ScholarPubMed
Redline, RW. Placental pathology: a systematic approach with clinical correlations. Placenta. 2008; 29 (Suppl. A): S86–91.Google Scholar
Cox, P, Marton, T. Pathological assessment of intrauterine growth restriction. Best Pract Res Clin Obstet Gynaecol. 2009; 23: 751–64.Google Scholar
Klaritsch, P, Haeusler, M, Karpf, E, Schlembach, D, Lang, U. Spontaneous intrauterine umbilical artery thrombosis leading to severe fetal growth restriction. Placenta. 2008; 29: 374–7.Google Scholar
Reister, F, Frank, HG, Kingdom, JC, Heyl, W, Kaufmann, P, Rath, W, et al. Macrophage-induced apoptosis limits endovascular trophoblast invasion in the uterine wall of preeclamptic women. Lab Invest. 2001; 81: 1143–52.CrossRefGoogle ScholarPubMed
Contro, E, deSouza, R, Bhide, A. Chronic intervillositis of the placenta: a systematic review. Placenta. 2010; 31: 1106–10.Google Scholar
Uxa, R, Baczyk, D, Kingdom, JC, Viero, S, Casper, R, Keating, S. Genetic polymorphisms in the fibrinolytic system of placentas with massive perivillous fibrin deposition. Placenta. 2010; 31: 499–505.Google Scholar
Fitzgerald, B, Baczyk, D, J. K, Keating, S. Villous Cytotrophoblast Phenotype Switching in Massive Perivillous Fibrinoid Deposition. Submitted for publication. 2011.Google Scholar
Boog, G. Chronic villitis of unknown etiology. Eur J Obstet Gynecol Reprod Biol. 2008; 136: 9–15.CrossRefGoogle ScholarPubMed
Katzman, PJ, Murphy, SP, Oble, DA. Immunohistochemical analysis reveals an influx of regulatory T cells and focal trophoblastic STAT-1 phosphorylation in chronic villitis of unknown etiology. Pediatr Dev Pathol. 2011; 14: 284–93.Google Scholar
Tang, Z, Abrahams, VM, Mor, G, Guller, S. Placental Hofbauer cells and complications of pregnancy. Ann N Y Acad Sci. 2011; 1221: 103–8.Google Scholar
Derricott, H, Jones, RL, Greenwood, SL, Batra, G, Evans, MJ, Heazell, AE. Characterizing villitis of unknown etiology and inflammation in stillbirth. Am J Pathol. 2016; 186: 952–61.Google Scholar
Levytska, K, Higgins, M, Keating, S, Melamed, N, Walker, M, Sebire, NJ, et al. Placental pathology in relation to uterine artery doppler findings in pregnancies with severe intrauterine growth restriction and abnormal umbilical artery doppler changes. Am J Perinatol. 2017; 34: 451–7.Google Scholar
Walker, MG, Hindmarsh, PC, Geary, M, Kingdom, JC. Sonographic maturation of the placenta at 30 to 34 weeks is not associated with second trimester markers of placental insufficiency in low-risk pregnancies. J Obstet Gynaecol Can. 2010; 32: 1134–9.Google Scholar
Cooley, SM, Donnelly, JC, Walsh, T, McMahon, C, Gillan, J, Geary, MP. The impact of ultrasonographic placental architecture on antenatal course, labor and delivery in a low-risk primigravid population. J Matern Fetal Neonatal Med. 2011; 24: 493–7.Google Scholar
Laskin, CA, Bombardier, C, Hannah, ME, Mandel, FP, Ritchie, JW, Farewell, V, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med. 1997; 337: 148–53.Google Scholar
Rodger, MA, Gris, JC, de Vries, JIP, Martinelli, I, Rey, E, Schleussner, E, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet. 2016; 388: 2629–41.Google Scholar
Wat, JM, Audette, M, Kingdom, JC. Molecular actions of heparin and their implications in preventing preeclampsia. J Thromb Haemost. 2018; 16 [Epub ahead of print]Google Scholar
Bewley, S, Cooper, D, Campbell, S. Doppler investigation of uteroplacental blood flow resistance in the second trimester: a screening study for pre-eclampsia and intrauterine growth retardation. BJOG. 1991; 98: 871–9.Google Scholar
Yu, CK, Smith, GC, Papageorghiou, AT, Cacho, AM, Nicolaides, KH. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol. 2005; 193: 429–36.Google Scholar
Pardi, G, Cetin, I, Marconi, AM, Bozzetti, P, Buscaglia, M, Makowski, EL, et al. Venous drainage of the human uterus: respiratory gas studies in normal and fetal growth-retarded pregnancies. Am J Obstet Gynecol. 1992; 166: 699–706.Google Scholar
Alkazaleh, F, Chaddha, V, Viero, S, Malik, A, Anastasiades, C, Sroka, H, et al. Second-trimester prediction of severe placental complications in women with combined elevations in alpha-fetoprotein and human chorionic gonadotrophin. Am J Obstet Gynecol. 2006; 194: 821–7.Google Scholar
Huang, T, Hoffman, B, Meschino, W, Kingdom, J, Okun, N. Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of Down syndrome. Prenat Diagn. 2010; 30: 471–7.Google Scholar
Schwartz, N, Coletta, J, Pessel, C, Feng, R, Timor-Tritsch, IE, Parry, S, et al. Novel 3-dimensional placental measurements in early pregnancy as predictors of adverse pregnancy outcomes. J Ultrasound Med. 2010; 29: 1203–12.CrossRefGoogle ScholarPubMed
Kingdom, JC, Walker, M, Proctor, LK, Keating, S, Shah, PS, McLeod, A, et al. Unfractionated heparin for second trimester placental insufficiency: a pilot randomized trial. J Thromb Haemost. 2011; 9: 1483–92.Google Scholar
McLaughlin, K, Baczyk, D, Potts, A, Hladunewich, M, Parker, JD, Kingdom, JC. Low molecular weight heparin improves endothelial function in pregnant women at high risk of preeclampsia. Hypertension. 2017; 69: 180–8.Google Scholar
Myers, JE, Kenny, LC, McCowan, LM, Chan, EH, Dekker, GA, Poston, L, et al. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG. 2013; 120: 1215–23.Google Scholar
McLaughlin, K, Scholten, RR, Parker, JD, Ferrazzi, E, Kingdom, JCP. Low molecular weight heparin for the prevention of severe preeclampsia: where next? Br J Clin Pharmacol. 2018; 84: 673–8.Google Scholar
Preston, FE, Rosendaal, FR, Walker, ID, Briet, E, Berntorp, E, Conard, J, et al. Increased fetal loss in women with heritable thrombophilia. Lancet. 1996; 348: 913–16.Google Scholar
Mousa, HA, Alfirevic, Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum Reprod. 2000; 15: 1830–3.Google Scholar
Farine, D, Ryan, G, Kelly, EN, Morrow, RJ, Laskin, C, Ritchie, JW. Absent end-diastolic flow velocity waveforms in the umbilical artery—the subsequent pregnancy. Am J Obstet Gynecol. 1993; 168: 637–40.Google Scholar
Toal, M, Chan, C, Fallah, S, Alkazaleh, F, Chaddha, V, Windrim, RC, et al. Usefulness of a placental profile in high-risk pregnancies. Am J Obstet Gynecol. 2007; 196: 363. e1–7.Google Scholar
Staff, AC, Dechend, R, Pijnenborg, R. Learning from the placenta: acute atherosis and vascular remodeling in preeclampsia – novel aspects for atherosclerosis and future cardiovascular health. Hypertension. 2010; 56: 1026–34.Google Scholar

References

Royal College of Obstetricians and Gynaecologists. (2014). The Investigation and Management of the Small-for-Gestational-Age Fetus. Green-top Guideline No. 31. https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_31.pdfGoogle Scholar
Flenady, V, Middleton, P, Smith, GC, Duke, W, Erwich, JJ, Khong, TY, et al. Stillbirths: the way forward in high-income countries. Lancet. 2011; 377: 1703–17.CrossRefGoogle ScholarPubMed
Gardosi, J, Madurasinghe, V, Williams, M, Malik, A, Francis, A. Maternal and fetal risk factors for stillbirth: population based study. BMJ. 2013; 346: f108.Google Scholar
Barker, DJ, Osmond, C. Infant mortality, childhood nutrition, and ischaemic heart disease in England and Wales. Lancet. 1986; 1: 1077–81.Google Scholar
Mifsud, W, Sebire, NJ. Placental pathology in early-onset and late-onset fetal growth restriction. Fetal Diagn Ther. 2014; 36: 117–28.Google Scholar
Gordijn, SJ, Beune, IM, Thilaganathan, B, Papageorghiou, A, Baschat, AA, Baker, PN, et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol. 2016; 48: 333–9.Google Scholar
Lean, SC, Derricott, H, Jones, RL, Heazell, AEP. Advanced maternal age and adverse pregnancy outcomes: a systematic review and meta-analysis. PLoS ONE. 2017; 12: e0186287.Google Scholar
Flenady, V, Koopmans, L, Middleton, P, Froen, JF, Smith, GC, Gibbons, K, et al. Major risk factors for stillbirth in high-income countries: a systematic review and meta-analysis. Lancet. 2011; 377: 1331–40.Google Scholar
Schieve, LA, Meikle, SF, Ferre, C, Peterson, HB, Jeng, G, Wilcox, LS. Low and very low birth weight in infants conceived with use of assisted reproductive technology. N Engl J Med. 2002; 346: 731–7.Google Scholar
Lawn, JE, Blencowe, H, Waiswa, P, Amouzou, A, Mathers, C, Hogan, D, et al. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet. 2016; 387: 587–603.Google Scholar
McDonald, SD, Han, Z, Mulla, S, Murphy, KE, Beyene, J, Ohlsson, A. Preterm birth and low birth weight among in vitro fertilization singletons: a systematic review and meta-analyses. Eur J Obstet Gynecol Reprod Biol. 2009; 146: 138–48.Google Scholar
Helmerhorst, FM, Perquin, DA, Donker, D, Keirse, MJ. Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies. BMJ. 2004; 328: 261.CrossRefGoogle Scholar
Steegers, EA, von Dadelszen, P, Duvekot, JJ, Pijnenborg, R. Pre-eclampsia. Lancet. 2010; 376: 631–44.Google Scholar
Schreiber, K, Radin, M, Sciascia, S. Current insights in obstetric antiphospholipid syndrome. Curr Opin Obstet Gynecol. 2017; 29: 397–403.Google Scholar
Sammaritano, LR. Management of systemic lupus erythematosus during pregnancy. Annu Rev Med. 2017; 68: 271–85.Google Scholar
Foo, FL, Mahendru, AA, Masini, G, Fraser, A, Cacciatore, S, MacIntyre, DA, et al. Association between prepregnancy cardiovascular function and subsequent preeclampsia or fetal growth restriction. Hypertension. 2018; 72: 442–50.Google Scholar
Tay, J, Foo, L, Masini, G, Bennett, PR, McEniery, CM, Wilkinson, IB, et al. Early and late preeclampsia are characterized by high cardiac output, but in the presence of fetal growth restriction, cardiac output is low: insights from a prospective study. Am J Obstet Gynecol. 2018; 218: 517. e1–e12.Google Scholar
Simcox, LE, Ormesher, L, Tower, C, Greer, IA. Thrombophilia and pregnancy complications. Int J Mol Sci. 2015; 16: 28418–28.Google Scholar
Rodger, MA, Gris, JC, de Vries, JIP, Martinelli, I, Rey, E, Schleussner, E, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet. 2016; 388: 2629–41.Google Scholar
Kingdom, JC, Drewlo, S. Is heparin a placental anticoagulant in high-risk pregnancies? Blood. 2011; 118: 4780–8.Google Scholar
Bundhun, PK, Soogund, MZ, Huang, F. Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: a meta-analysis of studies published between years 2001-2016. J Autoimmun. 2017; 79: 17–27.Google Scholar
Chakravarty, EF, Khanna, D, Chung, L. Pregnancy outcomes in systemic sclerosis, primary pulmonary hypertension, and sickle cell disease. Obstet Gynecol. 2008; 111: 927–34.Google Scholar
Greutmann, M, Pieper, PG. Pregnancy in women with congenital heart disease. Eur Heart J. 2015; 36: 2491–9.Google Scholar
Luewan, S, Srisupundit, K, Tongsong, T. Outcomes of pregnancies complicated by beta-thalassemia/hemoglobin E disease. Int J Gynaecol Obstet. 2009; 104: 203–5.Google Scholar
Mortola, JP, Frappell, PB, Aguero, L, Armstrong, K. Birth weight and altitude: a study in Peruvian communities. J Pediatr. 2000; 136: 324–9.Google Scholar
Stein, AD, Lumey, LH. The relationship between maternal and offspring birth weights after maternal prenatal famine exposure: the Dutch Famine Birth Cohort Study. Hum Biol. 2000; 72: 641–54.Google Scholar
Saccone, G, Berghella, V, Sarno, L, Maruotti, GM, Cetin, I, Greco, L, et al. Celiac disease and obstetric complications: a systematic review and metaanalysis. Am J Obstet Gynecol. 2016; 214: 225–34.Google Scholar
Khashan, AS, Henriksen, TB, Mortensen, PB, McNamee, R, McCarthy, FP, Pedersen, MG, et al. The impact of maternal celiac disease on birthweight and preterm birth: a Danish population-based cohort study. Hum Reprod. 2010; 25: 528–34.Google Scholar
Anjum, N, Baker, PN, Robinson, NJ, Aplin, JD. Maternal celiac disease autoantibodies bind directly to syncytiotrophoblast and inhibit placental tissue transglutaminase activity. Reprod Biol Endocrinol. 2009; 7: 16.Google Scholar
Kiefte-de Jong, JC, Jaddoe, VW, Uitterlinden, AG, Steegers, EA, Willemsen, SP, Hofman, A, et al. Levels of antibodies against tissue transglutaminase during pregnancy are associated with reduced fetal weight and birth weight. Gastroenterology. 2013; 144: 726–35. e2.Google Scholar
Suter, MA, Anders, AM, Aagaard, KM. Maternal smoking as a model for environmental epigenetic changes affecting birthweight and fetal programming. Mol Hum Reprod. 2013; 19: 1–6.Google Scholar
Blatt, K, Moore, E, Chen, A, Van Hook, J, DeFranco, EA. Association of reported trimester-specific smoking cessation with fetal growth restriction. Obstet Gynecol. 2015; 125: 1452–9.Google Scholar
Carter, RC, Jacobson, JL, Molteno, CD, Dodge, NC, Meintjes, EM, Jacobson, SW. Fetal alcohol growth restriction and cognitive impairment. Pediatrics. 2016; 138: e20160775.Google Scholar
Carter, RC, Wainwright, H, Molteno, CD, Georgieff, MK, Dodge, NC, Warton, F, et al. Alcohol, methamphetamine, and marijuana exposure have distinct effects on the human placenta. Alcohol Clin Exp Res. 2016; 40: 753–64.Google Scholar
Gundogan, F, Elwood, G, Longato, L, Tong, M, Feijoo, A, Carlson, RI, et al. Impaired placentation in fetal alcohol syndrome. Placenta. 2008; 29: 148–57.Google Scholar
Committee on Obstetric Practice. Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol. 2017; 130: e81–94.Google Scholar
Zedler, BK, Mann, AL, Kim, MM, Amick, HR, Joyce, AR, Murrelle, EL, et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction. 2016; 111: 2115–28.Google Scholar
Soto, E, Bahado-Singh, R. Fetal abnormal growth associated with substance abuse. Clin Obstet Gynecol. 2013; 56: 142–53.Google Scholar
Bada, HS, Das, A, Bauer, CR, Shankaran, S, Lester, B, Wright, LL, et al. Gestational cocaine exposure and intrauterine growth: maternal lifestyle study. Obstet Gynecol. 2002; 100: 916–24.Google Scholar
Kalaitzopoulos, DR, Chatzistergiou, K, Amylidi, AL, Kokkinidis, DG, Goulis, DG. Effect of methamphetamine hydrochloride on pregnancy outcome: a systematic review and meta-analysis. J Addict Med. 2018; 12: 220–6.Google Scholar
Ray, S, Stowe, ZN. The use of antidepressant medication in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2014; 28: 71–83.Google Scholar
Bloise, E, Feuer, SK, Rinaudo, PF. Comparative intrauterine development and placental function of ART concepti: implications for human reproductive medicine and animal breeding. Hum Reprod Update. 2014; 20: 822–39.Google Scholar
Snijders, RJ, Sherrod, C, Gosden, CM, Nicolaides, KH. Fetal growth retardation: associated malformations and chromosomal abnormalities. Am J Obstet Gynecol. 1993; 168: 547–55.Google Scholar
Rochelson, B, Kaplan, C, Guzman, E, Arato, M, Hansen, K, Trunca, C. A quantitative analysis of placental vasculature in the third-trimester fetus with autosomal trisomy. Obstet Gynecol. 1990; 75: 59–63.Google Scholar
Fujimoto, A, Wilson, MG. Growth retardation in Wolf-Hirschhorn syndrome. Hum Genet. 1990; 84: 296–7.Google Scholar
Sagi-Dain, L, Peleg, A, Sagi, S. Risk for chromosomal aberrations in apparently isolated intrauterine growth restriction: A systematic review. Prenat Diagn. 2017; 37: 1061–6.Google Scholar
Khoury, MJ, Erickson, JD, Cordero, JF, McCarthy, BJ. Congenital malformations and intrauterine growth retardation: a population study. Pediatrics. 1988; 82: 83–90.Google Scholar
Sun, L, Macgowan, CK, Sled, JG, Yoo, SJ, Manlhiot, C, Porayette, P, et al. Reduced fetal cerebral oxygen consumption is associated with smaller brain size in fetuses with congenital heart disease. Circulation. 2015; 131: 1313–23.Google Scholar
Naeye, RL. Unsuspected organ abnormalities associated with congenital heart disease. Am J Pathol. 1965; 47: 905–15.Google Scholar
Hamilton, ST, Scott, G, Naing, Z, Iwasenko, J, Hall, B, Graf, N, et al. Human cytomegalovirus-induces cytokine changes in the placenta with implications for adverse pregnancy outcomes. PLoS ONE. 2012; 7: e52899.Google Scholar
Adams Waldorf, KM, McAdams, RM. Influence of infection during pregnancy on fetal development. Reproduction. 2013; 146: R151–62.Google Scholar
Umbers, AJ, Aitken, EH, Rogerson, SJ. Malaria in pregnancy: small babies, big problem. Trends Parasitol. 2011; 27: 168–75.Google Scholar
McCarthy, FP, Giles, ML, Rowlands, S, Purcell, KJ, Jones, CA. Antenatal interventions for preventing the transmission of cytomegalovirus (CMV) from the mother to fetus during pregnancy and adverse outcomes in the congenitally infected infant. Cochrane Database Syst Rev. 2011; 3: CD008371.Google Scholar
Sassoon, DA, Castro, LC, Davis, JL, Hobel, CJ. Perinatal outcome in triplet versus twin gestations. Obstet Gynecol. 1990; 75: 817–20.Google Scholar
Coutinho Nunes, F, Domingues, AP, Vide Tavares, M, Belo, A, Ferreira, C, Fonseca, E, et al. Monochorionic versus dichorionic twins: are obstetric outcomes always different? J Obstet Gynaecol. 2016; 36: 598–601.Google Scholar
Stirrup, OT, Khalil, A, D’Antonio, F, Thilaganathan, B, Southwest Thames Obstetric Research Collaborative. Fetal growth reference ranges in twin pregnancy: analysis of the Southwest Thames Obstetric Research Collaborative (STORK) multiple pregnancy cohort. Ultrasound Obstet Gynecol. 2015; 45: 301–7.Google Scholar
Cheong-See, F, Schuit, E, Arroyo-Manzano, D, Khalil, A, Barrett, J, Joseph, KS, et al. Prospective risk of stillbirth and neonatal complications in twin pregnancies: systematic review and meta-analysis. BMJ. 2016; 354: i4353.Google Scholar
Hall, JG. Twinning. Lancet. 2003; 362: 735–43.Google Scholar
Sparks, TN, Nakagawa, S, Gonzalez, JM. Hypertension in dichorionic twin gestations: how is birthweight affected? J Matern Fetal Neonatal Med. 2017; 30: 380–5.Google Scholar
Lewi, L, Cannie, M, Blickstein, I, Jani, J, Huber, A, Hecher, K, et al. Placental sharing, birthweight discordance, and vascular anastomoses in monochorionic diamniotic twin placentas. Am J Obstet Gynecol. 2007; 197: 587. e1–8.Google Scholar
Audette, MC, Kingdom, JC. Screening for fetal growth restriction and placental insufficiency. Semin Fetal Neonatal Med. 2018; 23: 119–25.Google Scholar
Kingdom, JC, Audette, MC, Hobson, SR, Windrim, RC, Morgen, E. A placenta clinic approach to the diagnosis and management of fetal growth restriction. Am J Obstet Gynecol. 2018; 218: S803–17.Google Scholar
Pay, AS, Wiik, J, Backe, B, Jacobsson, B, Strandell, A, Klovning, A. Symphysis-fundus height measurement to predict small-for-gestational-age status at birth: a systematic review. BMC Pregnancy Childbirth. 2015; 15: 22.Google Scholar
Robert Peter, J, Ho, JJ, Valliapan, J, Sivasangari, S. Symphysial fundal height (SFH) measurement in pregnancy for detecting abnormal fetal growth. Cochrane Database Syst Rev. 2015; 9: CD008136.Google Scholar
Hadlock, FP, Harrist, RB, Sharman, RS, Deter, RL, Park, SK. Estimation of fetal weight with the use of head, body, and femur measurements—a prospective study. Am J Obstet Gynecol. 1985; 151: 333–7.Google Scholar
Papageorghiou, AT, Ohuma, EO, Altman, DG, Todros, T, Cheikh Ismail, L, Lambert, A, et al. International standards for fetal growth based on serial ultrasound measurements: the Fetal Growth Longitudinal Study of the INTERGROWTH-21st Project. Lancet. 2014; 384: 869–79.Google Scholar
Gardosi, J. Customized fetal growth standards: rationale and clinical application. Semin Perinatol. 2004; 28: 33–40.Google Scholar
Ego, A, Subtil, D, Grange, G, Thiebaugeorges, O, Senat, MV, Vayssiere, C, et al. Customized versus population-based birth weight standards for identifying growth restricted infants: a French multicenter study. Am J Obstet Gynecol. 2006; 194: 1042–9.Google Scholar
Reddy, M, Wallace, EM, Mockler, JC, Stewart, L, Knight, M, Hodges, R, et al. Maternal Asian ethnicity and obstetric intrapartum intervention: a retrospective cohort study. BMC Pregnancy Childbirth. 2017; 17: 3.Google Scholar
Lockie, E, McCarthy, EA, Hui, L, Churilov, L, Walker, SP. Feasibility of using self-reported ethnicity in pregnancy according to the gestation-related optimal weight classification: a cross-sectional study. BJOG. 2018; 125: 704–9.Google Scholar
Kiserud, T, Piaggio, G, Carroli, G, Widmer, M, Carvalho, J, Neerup Jensen, L, et al. The World Health Organization Fetal Growth Charts: A Multinational Longitudinal Study of Ultrasound Biometric Measurements and Estimated Fetal Weight. PLoS Medicine. 2017; 14: e1002220.Google Scholar
Bricker, L, Medley, N, Pratt, JJ. Routine ultrasound in late pregnancy (after 24 weeks’ gestation). Cochrane Database Syst Rev. 2015; 6: CD001451.Google Scholar
Sovio, U, White, IR, Dacey, A, Pasupathy, D, Smith, GCS. Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the Pregnancy Outcome Prediction (POP) study: a prospective cohort study. Lancet. 2015; 386: 2089–97.Google Scholar
Monier, I, Blondel, B, Ego, A, Kaminiski, M, Goffinet, F, Zeitlin, J. Poor effectiveness of antenatal detection of fetal growth restriction and consequences for obstetric management and neonatal outcomes: a French national study. BJOG. 2015; 122: 518–27.Google Scholar
Deter, RL. Individualized growth assessment: evaluation of growth using each fetus as its own control. Semin Perinatol. 2004; 28: 23–32.Google Scholar
Kingdom, JC, Burrell, SJ, Kaufmann, P. Pathology and clinical implications of abnormal umbilical artery Doppler waveforms. Ultrasound Obstet Gynecol. 1997; 9: 271–86.Google Scholar
Alfirevic, Z, Stampalija, T, Dowswell, T. Fetal and umbilical Doppler ultrasound in high-risk pregnancies. Cochrane Database Syst Rev. 2017; 6: CD007529.Google Scholar
Alfirevic, Z, Stampalija, T, Medley, N. Fetal and umbilical Doppler ultrasound in normal pregnancy. Cochrane Database Syst Rev. 2015; 4: CD001450.Google Scholar
Rodriguez, A, Tuuli, MG, Odibo, AO. First-, second-, and third-trimester screening for preeclampsia and intrauterine growth restriction. Clin Lab Med. 2016; 36: 331–51.Google Scholar
Roberts, LA, Ling, HZ, Poon, L, Nicolaides, KH, Kametas, NA. Maternal hemodynamics, fetal biometry and Dopplers in pregnancies followed up for suspected fetal growth restriction. Ultrasound Obstet Gynecol. 2018; 52: 507–14.Google Scholar
Smith, GC. First-trimester determination of complications of late pregnancy. JAMA. 2010; 303: 561–2.Google Scholar
Gaccioli, F, Aye, I, Sovio, U, Charnock-Jones, DS, Smith, GCS. Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. Am J Obstet Gynecol. 2018; 218: S725–37.Google Scholar
Tan, MY, Poon, LC, Rolnik, DL, Syngelaki, A, de Paco Matallana, C, Akolekar, R, et al. Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE. Ultrasound Obstet Gynecol. 2018; 52: 52–9.Google Scholar
Sovio, U, Smith, GCS. The effect of customization and use of a fetal growth standard on the association between birthweight percentile and adverse perinatal outcome. Am J Obstet Gynecol. 2018; 218: S738–44.Google Scholar
Griffin, M, Seed, PT, Duckworth, S, North, R, Myers, J, Mackillop, L, et al. Predicting delivery of a small-for-gestational-age infant and adverse perinatal outcome in women with suspected pre-eclampsia. Ultrasound Obstet Gynecol. 2018; 51: 387–95.Google Scholar
Sharp, A, Chappell, LC, Dekker, G, Pelletier, S, Garnier, Y, Zeren, O, et al. Placental Growth Factor informed management of suspected pre-eclampsia or fetal growth restriction: the MAPPLE cohort study. Pregnancy Hypertens. 2018; 14: 228–33.Google Scholar
Ormesher, L, Johnstone, ED, Shawkat, E, Dempsey, A, Chmiel, C, Ingram, E, et al. A clinical evaluation of placental growth factor in routine practice in high-risk women presenting with suspected pre-eclampsia and/or fetal growth restriction. Pregnancy Hypertens. 2018; 14: 243–9.Google Scholar
Griffin, M, Seed, PT, Webster, L, Myers, J, MacKillop, L, Simpson, N, et al. Diagnostic accuracy of placental growth factor and ultrasound parameters to predict the small-for-gestational-age infant in women presenting with reduced symphysis-fundus height. Ultrasound Obstet Gynecol. 2015; 46: 182–90.Google Scholar
Lees, C, Marlow, N, Arabin, B, Bilardo, CM, Brezinka, C, Derks, JB, et al. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE). Ultrasound Obstet Gynecol. 2013; 42: 400–8.Google Scholar
Figueras, F, Caradeux, J, Crispi, F, Eixarch, E, Peguero, A, Gratacós, E. Diagnosis and surveillance of late-onset fetal growth restriction. Am J Obstet Gynecol. 2018; 218: S790–802. e1.Google Scholar
Figueras, F, Gratacós, E. An integrated approach to fetal growth restriction. Best Pract Res Clin Obstet Gynaecol. 2017; 38: 48–58.Google Scholar
Sebire, NJ. Umbilical artery Doppler revisited: pathophysiology of changes in intrauterine growth restriction revealed. Ultrasound Obstet Gynecol. 2003; 21: 419–22.Google Scholar
Caradeux, J, Martinez-Portilla, RJ, Basuki, TR, Kiserud, T, Figueras, F. Risk of fetal death in growth-restricted fetuses with umbilical and/or ductus venosus absent or reversed end-diastolic velocities before 34 weeks of gestation: a systematic review and meta-analysis. Am J Obstet Gynecol. 2018; 218: S774–82. e21.Google Scholar
Vollgraff Heidweiller-Schreurs, CA, De Boer, MA, Heymans, MW, Schoonmade, LJ, Bossuyt, PMM, Mol, BWJ, et al. Prognostic accuracy of cerebroplacental ratio and middle cerebral artery Doppler for adverse perinatal outcome: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018; 51: 313–22.Google Scholar
Grivell, RM, Alfirevic, Z, Gyte, GM, Devane, D. Antenatal cardiotocography for fetal assessment. Cochrane Database Syst Rev. 2015; 9: CD007863.Google Scholar
Pattison, N, McCowan, L. Cardiotocography for antepartum fetal assessment. Cochrane Database Syst Rev. 2000; 2: CD001068.Google Scholar
Frusca, T, Todros, T, Lees, C, Bilardo, CM, TRUFFLE Investigators. Outcome in early-onset fetal growth restriction is best combining computerized fetal heart rate analysis with ductus venosus Doppler: insights from the Trial of Umbilical and Fetal Flow in Europe. Am J Obstet Gynecol. 2018; 218: S783–9.Google Scholar
Lalor, JG, Fawole, B, Alfirevic, Z, Devane, D. Biophysical profile for fetal assessment in high risk pregnancies. Cochrane Database Syst Rev. 2008; 1: CD000038.Google Scholar
Kaur, S, Picconi, JL, Chadha, R, Kruger, M, Mari, G. Biophysical profile in the treatment of intrauterine growth-restricted fetuses who weigh <1000 g. Am J Obstet Gynecol. 2008; 199: 264. e1–4.Google Scholar
Thornton, JG, Hornbuckle, J, Vail, A, Spiegelhalter, DJ, Levene, M, GRIT Study Group. Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomised controlled trial. Lancet. 2004; 364: 513–20.Google Scholar
Walker, DM, Marlow, N, Upstone, L, Gross, H, Hornbuckle, J, Vail, A, et al. The Growth Restriction Intervention Trial: long-term outcomes in a randomized trial of timing of delivery in fetal growth restriction. Am J Obstet Gynecol. 2011; 204: 34. e1–9.Google Scholar
Lees, CC, Marlow, N, van Wassenaer-Leemhuis, A, Arabin, B, Bilardo, CM, Brezinka, C, et al. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet. 2015; 385: 2162–72.Google Scholar
Ting, JY, Kingdom, JC, Shah, PS. Antenatal glucocorticoids, magnesium sulfate, and mode of birth in preterm fetal small for gestational age. Am J Obstet Gynecol. 2018; 218: S818–28.Google Scholar
Lee, HC, Gould, JB. Survival rates and mode of delivery for vertex preterm neonates according to small- or appropriate-for-gestational-age status. Pediatrics. 2006; 118: e1836–44.Google Scholar
Boers, KE, Vijgen, SM, Bijlenga, D, van der Post, JA, Bekedam, DJ, Kwee, A, et al. Induction versus expectant monitoring for intrauterine growth restriction at term: randomised equivalence trial (DIGITAT). BMJ. 2010; 341: c7087.Google Scholar
van Wyk, L, Boers, KE, van der Post, JA, van Pampus, MG, van Wassenaer, AG, van Baar, AL, et al. Effects on (neuro)developmental and behavioral outcome at 2 years of age of induced labor compared with expectant management in intrauterine growth-restricted infants: long-term outcomes of the DIGITAT trial. Am J Obstet Gynecol. 2012; 206: 406. e1–7.Google Scholar
Meher, S, Duley, L, Hunter, K, Askie, L. Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol. 2017; 216: 121–8. e2.Google Scholar
Groom, KM, David, AL. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. Am J Obstet Gynecol. 2018; 218: S829–40.Google Scholar
Rolnik, DL, Wright, D, Poon, LC, O’Gorman, N, Syngelaki, A, de Paco Matallana, C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New Engl J Med. 2017; 377: 613–22.Google Scholar
Wat, JM, Audette, MC, Kingdom, JC. Molecular actions of heparin and their implications in preventing pre-eclampsia. J Thromb Haemost. 2018 [ePub ahead of print].Google Scholar
National Health and Medical Research Council (Australia). (2010). Antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant and child. National Clinical Practice Guidelines. https://www.clinicalguidelines.gov.au/register/antenatal-magnesium-sulphate-prior-preterm-birth-neuroprotection-fetus-infant-and-childGoogle Scholar
Stockley, EL, Ting, JY, Kingdom, JC, McDonald, SD, Barrett, JF, Synnes, AR, et al. Intrapartum magnesium sulfate is associated with neuroprotection in growth-restricted fetuses. Am J Obstet Gynecol. 2018; 219: 606. e1–e8.Google Scholar
Nawathe, A, David, AL. Prophylaxis and treatment of foetal growth restriction. Best Pract Res Clin Obstet Gynaecol. 2018; 49: 66–78.Google Scholar
Wright, E, Audette, MC, Ye, XY, Keating, S, Hoffman, B, Lye, SJ, et al. Maternal vascular malperfusion and adverse perinatal outcomes in low-risk nulliparous women. Obstet Gynecol. 2017; 130: 1112–20.Google Scholar

References

Resnik, R. Intrauterine growth restriction. Obstet Gynecol. 2002; 99: 490–6.Google Scholar
Levine, TA, Grunau, RE, McAuliffe, FM, Pinnamaneni, R, Foran, A, Alderdice, FA. Early childhood neurodevelopment after intrauterine growth restriction: a systematic review. Pediatrics. 2015; 135: 126–41.Google Scholar
Barker, DJP. Adult consequences of fetal growth restriction. Clin Obstet Gynecol. 2006; 49: 270–83.Google Scholar
Gaillard, R, Steegers, EAP, de Jongste, JC, Hofman, A, Jaddoe, VWV. Tracking of fetal growth characteristics during different trimesters and the risks of adverse birth outcomes. Int J Epidemiol. 2014; 43: 1140–53.Google Scholar
Gardosi, J, Kady, SM, McGeown, P, Francis, A, Tonks, A. Classification of stillbirth by relevant condition at death (ReCoDe): population based cohort study. BMJ. 2005; 331: 1113.Google Scholar
Partap, U, Sovio, U, Smith, GC. Fetal growth and the risk of spontaneous preterm birth in a prospective cohort study of nulliparous women. Am J Epidemiol. 2016; 184: 110–19.Google Scholar
Lees, C, Marlow, N, Arabin, B, Bilardo, CM, Brezinka, C, et al. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the Trial of Randomized Umbilical and Fetal Flow in Europe (TRUFFLE). Ultrasound Obstet Gynecol. 2013; 42: 400–8.Google Scholar
Walker, DM, Marlow, N. Neurocognitive outcome following fetal growth restriction. Arch Dis Child Fetal Neonatal Ed. 2008; 93: F322–5.Google Scholar
Barker, DJP, Godfrey, KM, Gluckman, PD, Harding, JE, Owens, JA, Robinson, JS. Fetal nutrition and cardiovascular disease in adult life. Lancet. 1993; 341: 938–41.Google Scholar
Smith, GC, Wood, AM, White, IR, Pell, JP, Hattie, J. Birth weight and the risk of cardiovascular disease in the maternal grandparents. Am J Epidemiol. 2010; 171: 736–44.Google Scholar
Smith, GCS, Smith, MFS, McNay, MB, Fleming, JEE. First-trimester growth and the risk of low birth weight. N Engl J Med. 1998; 339: 1817–22.Google Scholar
Hadlock, FP, Harrist, RB, Sharman, RS, Deter, RL, Park, SK. Estimation of fetal weight with the use of head, body and femur measurements: A prospective study. Am J Obstet Gynecol. 1985; 151: 333–7.Google Scholar
Royal College of Obstetricians and Gynaecologists. (2014). The Investigation and Management of the Small-for-Gestational-Age Fetus. Green-top Guideline No. 31. www.rcog.org.uk/globalassets/documents/guidelines/gtg_31.pdfGoogle Scholar
Sovio, U, White, IR, Dacey, A, Pasuparthy, D, Smith, GCS. Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the Pregnancy Outcome Prediction (POP) study: a prospective cohort study. Lancet. 2015; 386: 2089–97.Google Scholar
Clausson, B, Gardosi, J, Francis, A, Cnattingius, S. Perinatal outcome in SGA births defined by customised versus population-based birthweight standards. BJOG. 2001; 108 : 830–4.Google Scholar
Carberry, AE, Gordon, A, Bond, DM, Hyett, J, Raynes-Greenow, CH, Jeffery, HE. Customised versus population-based growth charts as a screening tool for detecting small for gestational age infants in low-risk pregnant women. Cochrane Database Syst Rev. 2014; 5: CD008549.Google Scholar
Iliodromiti, S, Mackay, DF, Smith, GCS, Pell, JP, Sattar, N, Lawlor, DA, et al. Customised and noncustomised birth weight centiles and prediction of stillbirth and infant mortality and morbidity: a cohort study of 979,912 term singleton pregnancies in Scotland. PLoS Med. 2017; 14: e1002228Google Scholar
Martin, AM, Bindra, R, Curcio, P, Cicero, S, Nicolaides, KH. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation. Ultrasound Obstet Gynecol. 2001; 18: 583–6.Google Scholar
Smith, GC, Yu, CK, Papageorghiou, AT, Cacho, AM, Nicolaides, KH, Fetal Medicine Foundation Second Trimester Screening Group. Maternal uterine Doppler flow velocimetry and the risk of stillbirth. Obstet Gynecol. 2007; 109: 144–51.Google Scholar
Figueras, F, Gratacós, E. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther. 2014; 36: 86–98.Google Scholar
Eixarch, E, Meler, E, Iraola, A, Illa, M, Crispi, F, Hernandez-Andrade, E, et al. Neurodevelopmental outcome in 2-year-old infants who were small-for-gestational age term fetuses with cerebral blood flow redistribution. Ultrasound Obstet Gynecol. 2008; 32: 894–9.Google Scholar
Khalil, A, Morales-Roselló, J, Townsend, R, Morlando, M, Papageorghiou, A, Bhide, A, et al. Value of third-trimester cerebroplacental ratio and uterine artery Doppler indices as predictors of stillbirth and perinatal loss. Ultrasound Obstet Gynecol. 2016; 47: 74–80.Google Scholar
Vollgraff Heidweiller-Schreurs, CA, De Boer, MA, Heymans, MW, Schoonmade, LJ, Bossuyt, PMM, Mol, BWJ, et al. Prognostic accuracy of cerebroplacental ratio and middle cerebral artery Doppler for adverse perinatal outcome: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2017; 51: 313–22.Google Scholar
Morris, RK, Selman, TJ, Verma, M, Robson, SC, Kleijnen, J, Khan, KS. Systematic review and meta-analysis of the test accuracy of ductus venosus Doppler to predict compromise of fetal/neonatal wellbeing in high risk pregnancies with placental insufficiency. Eur J Obstet Gynecol Reprod Biol. 2010; 152: 3–12.Google Scholar
Lees, CC, Marlow, N, vas Wassenaer-Leemhuis, A, Arabin, B, Bilardo, CM, Brezinka, C, et al. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet. 2015; 385: 2162–72.Google Scholar
Gaccioli, F, Aye, ILMH, Sovio, U, Charnock-Jones, DS, Smith, GCS. Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. Am J Obstet Gynecol. 2018; 218: S725–37.Google Scholar
Smith, GC, Stenhouse, EJ, Crossley, JA, Aitken, DA, Cameron, AD, Connor, JM. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia and stillbirth. J Clin Endocrinol Metab. 2002; 87: 1762–7.Google Scholar
Dugoff, L, Hobbins, JC, Malone, FD, Vidaver, J, Sullivan, L, Canick, JA, et al. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol. 2005; 106: 260–7.Google Scholar
McCowan, LME, Thompson, JMD, Taylor, RS, Baker, PN, North, RA, Poston, L, et al. Prediction of small for gestational age infants in healthy nulliparous women using clinical and ultrasound risk factors combined with early pregnancy biomarkers. PLoS One. 2017; 12: e0169311.Google Scholar
Smith, GC, Shah, I, Crossley, JA, Aitken, DA, Pell, JP, Nelson, SM, et al. Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol. 2006; 107: 161–6.Google Scholar
Lesmes, C, Gallo, DM, Gonzalez, R, Poon, LC, Nicolaides, KH. Prediction of small-for-gestational-age neonates: screening by maternal serum biochemical markers at 19–24 weeks. Ultrasound Obstet Gynecol. 2015; 46: 341–9.Google Scholar
Karagiannis, G, Akolekar, R, Sarquis, R, Wright, D, Nicolaides, KH. Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11–13 weeks. Fetal Diagn Ther. 2011; 29: 148–54.Google Scholar
Valiño, N, Giunta, G, Gallo, DM, Akolekar, R, Nicolaides, KH. Biophysical and biochemical markers at 30–34 weeks’ gestation in the prediction of adverse perinatal outcome. Ultrasound Obstet Gynecol. 2016; 47: 194–202.Google Scholar
Valiño, N, Giunta, G, Gallo, DM, Akolekar, R, Nicolaides, KH. Biophysical and biochemical markers at 35–37 weeks’ gestation in the prediction of adverse perinatal outcome. Ultrasound Obstet Gynecol. 2016; 47: 203–9.Google Scholar
Cleaton, MAM, Dent, CL, Howard, M, Corish, JA, Gutteridge, I, Sovio, U, et al. Fetus-derived DLK1 is required for maternal metabolic adaptations to pregnancy and is associated with fetal growth restriction. Nat Genet. 2016; 48: 1473–80.Google Scholar
Hutcheon, JA, Zhang, X, Platt, RW, Cnattingius, S, Kramer, MS. The case against customised birthweight standards. Paediatr Perinat Epidemiol. 2011; 25: 11–16.Google Scholar
Gaccioli, F, Sovio, U, Cook, E, Hund, M, Charnock-Jones, DS, Smith, GCS. Screening for fetal growth restriction using ultrasound and the sFLT1:PlGF ratio in a prospective cohort study of nulliparous women. Lancet Child Adolesc Health. 2018; 2: 569–81.Google Scholar
Duley, L, Henderson-Smart, DJ, Meher, S, King, JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007; 2: CD004659.Google Scholar
Groom, KM, McCowan, LM, Mackay, LK, Lee, AC, Said, JM, Kane, SC, et al. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial. Am J Obstet Gynecol. 2017; 216: e1–296.Google Scholar
Sharp, A, Cornforth, C, Jackson, R, Harrold, J, Turner, MA, Kenny, LC, et al. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. Lancet Child Adolesc Health. 2018; 2: 93–102.Google Scholar
Wyrwoll, CS, Noble, J, Thomson, A, Tesic, D, Miller, MR, Rog-Zielinska, EA, et al. Pravastatin ameliorates placental vascular defects, fetal growth, and cardiac function in a model of glucocorticoid excess. Proc Natl Acad Sci U S A. 2016; 113: 6265–70.Google Scholar
Brownfoot, FC, Tong, S, Hannan, NJ, Binder, NK, Walker, SP, Cannon, P, et al. Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension. 2015; 66: 687–97.Google Scholar
Brownfoot, FC, Hastie, R, Hannan, NJ, Cannon, P, Tuohey, L, Parry, LJ, et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol. 2016; 214: e1–356.Google Scholar
Nawaz, FH, Khalid, R, Naru, T, Rizvi, J. Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome? J Obstet Gynecol Res. 2008; 34: 832–7.Google Scholar
Onda, K, Tong, S, Beard, S, Binder, N, Muto, M, Senadheera, SN, et al. Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension and rescue endothelial dysfunction. Hypertension. 2017; 69: 457–68.Google Scholar
Miller, SL, Yawno, T, Alers, NO, Castillo-Melendez, M, Supramaniam, VG, van Zyl, N, et al. Antenatal antioxidant treatment with melatonin to decrease newborn neurodevelopmental deficits and brain injury caused by fetal growth restriction. J Pineal Res. 2014; 56: 283–94.Google Scholar
Chang, EY, Barbosa, E, Paintila, MK, Singh, A, Singh, I. The use of N-acetylcysteine for the prevention of hypertension in the reduced uterine perfusion pressure model for preeclampsia in Sprague-Dawley rats. Am J Obstet Gynecol. 2005; 193: 952–6.Google Scholar
Roes, EM, Raijmakers, MT, de Boo, TM, Zusterzeel, PL, Merkus, HM, Peters, WH, et al. Oral N-acetylcysteine administration does not stabilise the process of established severe preeclampsia. Eur J Obstet Gynecol. 2006; 127: 61–7.Google Scholar
Soothill, PW, Nicolaides, KH, Bilardo, CM, Campbell, S. Relation of fetal hypoxia in growth retardation to mean blood velocity in the fetal aorta. Lancet. 1986; 2: 1118–20.Google Scholar
GRIT Study Group. A randomised trial of timed delivery for the compromised preterm fetus: short-term outcomes and Bayesian interpretation. BJOG. 2003; 110: 27–32.Google Scholar
Walker, DM, Marlow, N, Upstone, L, Gross, H, Hornbuckle, J, Vail, A, et al. The Growth Restriction Intervention Trial: long-term outcomes in a randomized trial of timing of delivery in fetal growth restriction. Am J Obstet Gynecol. 2011; 2014: e1–9.Google Scholar
Morris, RK, Malin, G, Robson, SC, Kleijnen, J, Zamora, J, Khan, KS. Fetal umbilical artery Doppler to predict compromise of fetal/neonatal wellbeing in a high-risk population: systematic review and bivariate meta-analysis. Ultrasound Obstet Gynecol. 2011; 37: 135–42.Google Scholar
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin no. 134: fetal growth restriction. Obstet Gynecol. 2013; 121: 1122–33.Google Scholar
Whitehead, CL, Walker, SP, Mendis, S, Lappas, M, Tong, S. Quantifying mRNA coding growth genes in the maternal circulation to detect fetal growth restriction. Am J Obstet Gynecol. 2013; 209: e1–9.Google Scholar
Wӧlter, M, Rӧwer, C, Koy, C, Rath, W, Pecks, U, Glocker, MO. Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature. J Proteomics. 2016; 149: 44–52.Google Scholar
Maitre, L, Fthenou, E, Athersuch, T, Coen, M, Toledano, MB, Holmes, E, et al. Urinary metabolic profiles in early pregnancy are associated with preterm birth and fetal growth restriction in the Rhea mother–child cohort study. BMC Med. 2014; 12: 10.Google Scholar
Pantichob, N, Widdows, KL, Crocker, IP, Johnstone, ED, Please, CP, Sibley, CP, et al. Computational modelling of placental amino acid transfer as an integrated system. Biochim Biophys Acta. 2016; 1858: 1451–61.Google Scholar
Chappell, LC, David, AL. Improving the Pipeline for Developing and Testing Pharmacological Treatments in Pregnancy. PLoS Med. 2016; 13: e1002161.Google Scholar
King, A, Ndifon, C, Lui, S, Widdows, K, Kotamraju, VR, Agemy, L, et al. Tumor-homing peptides as tools for targeted delivery of payloads to the placenta. Sci Adv. 2016; 2: e1600349.Google Scholar
Cureton, N, Korotkova, I, Baker, B, Greenwood, S, Wareing, M, Kotamraji, VR, et al. Selective targeting of a novel vasodilator to the uterine vasculature to treat impaired uteroplacental perfusion in pregnancy. Theranostics. 2017; 7: 3715–31.Google Scholar
Spencer, R, Ambler, G, Brodszki, J, Diemert, A, Figueras, F, Gratacós, E, et al. EVERREST prospective study: a 6-year prospective study to define the clinical and biological characteristics of pregnancies affected by severe early onset fetal growth restriction. BMC Pregnancy Childbirth. 2017; 17: 43.Google Scholar

References

Brosens, I, Pijnenborg, R, Benagiano, G. Defective myometrial spiral artery remodelling as a cause of major obstetrical syndromes in endometriosis and adenomyosis. Placenta. 2013; 34: 100–5.Google Scholar
Lyall, F, Robson, SC, Bulmer, JN. Spiral artery remodeling and trophoblast invasion in preeclampsia and fetal growth restriction relationship to clinical outcome. Hypertension. 2013; 62: 1046–54.Google Scholar
Konje, JC, Howarth, ES, Kaufmann, P, Taylor, DJ. Longitudinal quantification of uterine artery blood volume flow changes during gestation in pregnancies complicated by intrauterine growth restriction. BJOG. 2003; 110: 301–5.Google Scholar
Savvidou, MD, Yu, CK, Harland, LC, Hingorani, AD, Nicolaides, KH. Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. Am J Obstet Gynecol. 2006; 195: 1668–73.Google Scholar
Timmermans, S, Steegers-Theunissen, RP, Vujkovic, M, den Breeijen, H, Russcher, H, Lindemans, J, et al. The Mediterranean diet and fetal size parameters: the Generation R Study. Br J Nutr. 2012; 108: 1399–409.Google Scholar
Mahon, P, Harvey, N, Crozier, S, Inskip, H, Robinson, S, Arden, NK, et al. Low maternal vitamin D status and fetal bone development: cohort study. J Bone Min Res. 2010; 25: 14–19.Google Scholar
Stephenson, J, Heslehurst, N, Hall, J, Schoenaker, DAJM, Hutchinson, J, Cade, JE, et al. Before the beginning: nutrition and lifestyle in the preconception period and its importance for future health. Lancet. 2018; 391: 1830–41.Google Scholar
Fleming, TP, Watkins, AJ, Velazquez, MA, Mathers, JC, Prentice, AM, Stephenson, J, et al. Origins of lifetime health around the time of conception: causes and consequences. Lancet. 2018; 391: 1842–52.Google Scholar
Hillman, S, Peebles, DM, Williams, DJ. Paternal metabolic and cardiovascular risk factors for fetal growth restriction: a case–control study. Diabetes Care. 2013; 36: 1675–80.Google Scholar
Barker, M, Dombrowski, SU, Colbourn, T, Fall, CHD, Kriznik, NM, Lawrence, WT, et al. Intervention strategies to improve nutrition and health behaviours before conception. Lancet. 2018; 391: 1853–64.Google Scholar
Knudsen, VK, Orozova-Bekkevold, IM, Mikkelsen, TB, Wolff, S, Olsen, SF. Major dietary patterns in pregnancy and fetal growth. Eur J Clin Nutr. 2008; 62: 463–70.Google Scholar
Ota, E, Hori, H, Mori, R, Tobe-Gai, R, Farrar, D. Antenatal dietary education and supplementation to increase energy and protein intake. Cochrane Database Syst Rev. 2015; 6: CD000032.Google Scholar
Haider, BA, Bhutta, ZA. Multiple-micronutrient supplementation for women during pregnancy. Cochrane Database Syst Rev. 2017; 4: CD004905.Google Scholar
Peña-Rosas, JP, De-Regil, LM, Gomez Malave, H, Flores-Urrutia, MC, Dowswell, T. Intermittent oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015; 11: CD009997.Google Scholar
Peña-Rosas, JP, De-Regil, LM, Garcia-Casal, MN, Dowswell, T. Daily oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015; 7: CD004736.Google Scholar
World Health Organization. (2013). Guideline: Calcium supplementation in pregnant women. https://apps.who.int/iris/bitstream/handle/10665/85120/9789241505376_eng.pdf;jsessionid=3C099F930FA697D0A123C32272A8838D?sequence=1.Google Scholar
Hofmeyr, GJ, Lawrie, TA, Atallah, ÁN, Duley, L, Torloni, MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2014; 6: CD001059.Google Scholar
Rumbold, A, Duley, L, Crowther, CA, Haslam, RR. Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev. 2008; 1: CD004227.Google Scholar
Han, Z, Mulla, S, Beyene, J, Liao, G, McDonald, SD, Knowledge Synthesis Group. Maternal underweight and the risk of preterm birth and low birth weight: a systematic review and meta-analyses. Int J Epidemiol. 2011; 40: 65–101.Google Scholar
Yaktine, AL, Rasmussen, KM (eds.). Weight Gain During Pregnancy: Reexamining the Guidelines. Washington, DC: National Academies Press, 2009.Google Scholar
Radulescu, L, Munteanu, O, Popa, F, Cirstoiu, M. The implications and consequences of maternal obesity on fetal intrauterine growth restriction. J Med Life. 2013; 6: 292–8.Google Scholar
CARE Study Group. Maternal caffeine intake during pregnancy and risk of fetal growth restriction: a large prospective observational study. BMJ. 2008; 337: a2332.Google Scholar
Wills, R-A, Coory, MD. Effect of smoking among Indigenous and non-Indigenous mothers on preterm birth and full-term low birthweight. Med J Aust. 2008; 189: 490–4.Google Scholar
Riisinen, S, Sankilampi, U, Gissler, M, Kramer, MR, Hakulinen-Viitanen, T, Saari, J, et al. Smoking cessation in the first trimester reduces most obstetric risks, but not the risks of major congenital anomalies and admission to neonatal care: a population-based cohort study of 1,164,953 singleton pregnancies in Finland. J Epidemiol Community Health. 2014; 68: 159–64.Google Scholar
Suzuki, K, Sato, M, Zheng, W, Shinohara, R, Yokomichi, H, Yamagata, Z. Effect of maternal smoking cessation before and during early pregnancy on fetal and childhood growth. J Epidemiol. 2014; 24: 60–6.Google Scholar
Lumley, J, Chamberlain, C, Dowswell, T, Oliver, S, Oakley, L, Watson, L. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2009; 3: CD001055.Google Scholar
Abraham, M, Alramadhan, S, Iniguez, C, Duijts, L, Jaddoe, VW, Den Dekker, HT, et al. A systematic review of maternal smoking during pregnancy and fetal measurements with meta-analysis. PLoS ONE. 2017; 12: e0170946.Google Scholar
Fergusson, DM, Horwood, LJ, Northstone, K. Maternal use of cannabis and pregnancy outcome. BJOG. 2002; 109: 21–7.Google Scholar
Gouin, K, Murphy, K, Shah, PS. Effects of cocaine use during pregnancy on low birthweight and preterm birth: Systematic review and metaanalyses. Am J Obstet Gynecol. 2011; 204: 340. e1–12.Google Scholar
Ladhani, NNN, Shah, PS, Murphy, KE. Prenatal amphetamine exposure and birth outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol. 2011; 205: 219. e1–219. e7.Google Scholar
Whitehead, N, Lipscomb, L. Patterns of alcohol use before and during pregnancy and the risk of small-for-gestational-age birth. Am J Epidemiol. 2003; 158: 654–62.Google Scholar
Patra, J, Bakker, R, Irving, H, Jaddoe, V, Malini, S, Rehm, J. Dose-response relationship between alcohol consumption before and during pregnancy and the risks of low birthweight, preterm birth and small for gestational age (SGA) – a systematic review and meta-analyses. BJOG. 2011; 118: 1411–21.Google Scholar
Abalos, E, Duley, L, Steyn, DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014; 1: CD002252.Google Scholar
Magee, LA, von Dadelszen, P, Rey, E, Ross, S, Asztalos, E, Murphy, KE, et al. Less-Tight versus Tight Control of Hypertension in Pregnancy. N Engl J Med. 2015; 372: 407–17.Google Scholar
Groom, KM, David, AL. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. Am J Obstet Gynecol. 2018; 218: S829–40.Google Scholar
Taubert, D, Berkels, R, Grosser, N, Schröder, H, Gründemann, D, Schömig, E. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol. 2004; 143: 159–65.Google Scholar
Grosser, N, Abate, A, Oberle, S, Vreman, HJ, Dennery, PA, Becker, JC, et al. Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun. 2003; 308: 956–60.Google Scholar
Roberge, S, Nicolaides, K, Demers, S, Hyett, J, Chaillet, N, Bujold, E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017; 216: 110–120. e6.Google Scholar
Meher, S, Duley, L, Hunter, K, Askie, L. Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol. 2017; 216: 121–128. e2.Google Scholar
Ayala, DE, Ucieda, R, Hermida, RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int. 2013; 30: 260–79.Google Scholar
Hermida, RC, Ayala, DE, Iglesias, M. Administration time-dependent influence of aspirin on blood pressure in pregnant women. Hypertension. 2003; 41: 651–6.Google Scholar
McCowan, LM, Figueras, F, Anderson, NH. Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy. Am J Obstet Gynecol. 2018: 218: S855–68.Google Scholar
Rolnik, DL, Wright, D, Poon, LC, O’Gorman, N, Syngelaki, A, de Paco Matallana, C, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017; 377: 613–22.Google Scholar
Omri, A, Delaloye, JF, Andersen, H, Bachmann, F. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost. 1989; 61: 55–6.Google Scholar
Mousavi, S, Moradi, M, Khorshidahmad, T, Motamedi, M. Anti-Inflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Sci. 2015; 2015: 507151.Google Scholar
Oberkersch, R, Attorresi, AI, Calabrese, GC. Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy. Thromb Res. 2010; 125: e240–5.Google Scholar
Mousa, SA, Petersen, LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost. 2009; 102: 258–67.Google Scholar
Bose, P, Black, S, Kadyrov, M, Bartz, C, Shlebak, A, Regan, L, et al. Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol. 2004; 191: 2125–31.Google Scholar
Sobel, ML, Kingdom, J, Drewlo, S. Angiogenic response of placental villi to heparin. Obstet Gynecol. 2011; 117: 1375–83.Google Scholar
Di Simone, N, Di Nicuolo, F, Sanguinetti, M, Ferrazzani, S, D’Alessio, MC, Castellani, R, et al. Low-molecular weight heparin induces in vitro trophoblast invasiveness: role of matrix metalloproteinases and tissue inhibitors. Placenta. 2007; 28: 298–304.Google Scholar
Yinon, Y, Ben Meir, E, Margolis, L, Lipitz, S, Schiff, E, Mazaki-Tovi, S, et al. Low molecular weight heparin therapy during pregnancy is associated with elevated circulatory levels of placental growth factor. Placenta. 2015; 36: 121–4.Google Scholar
McLaughlin, K, Baczyk, D, Potts, A, Hladunewich, M, Parker, JD, Kingdom, JCP. Low molecular weight heparin improves endothelial function in pregnant women at high risk of Preeclampsia. Hypertension. 2016; 1–9.Google Scholar
Torricelli, M, Reis, FM, Florio, P, Severi, FM, Bocchi, C, Picciolini, E, et al. Low-molecular-weight heparin improves the performance of uterine artery Doppler velocimetry to predict preeclampsia and small-for-gestational age infant in women with gestational hypertension. Ultrasound Med Biol. 2006; 32: 1431–5.Google Scholar
Abheiden, CNH, Van Hoorn, ME, Hague, WM, Kostense, PJ, Van Pampus, MG, De Vries, JIP. Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial Doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG. 2016; 123: 797–805.Google Scholar
de Vries, JIP, Hague, WM, van Pampus, MG. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a reply to a rebuttal. J Thromb Haemost. 2012; 10: 1196.Google Scholar
Rey, E, Garneau, P, David, M, Gauthier, R, Leduc, L, Michon, N, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009; 7: 58–64.Google Scholar
Mastrolia, SA, Novack, L, Thachil, J, Rabinovich, A, Pikovsky, O, Klaitman, V, et al. LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia: a systematic review and meta-analysis. Thromb Haemost. 2016; 116: 868–78.Google Scholar
Say, L, Gülmezoglu, AM, Hofmeyr, GJ. Maternal oxygen administration for suspected impaired fetal growth. Cochrane Database Syst Rev. 2003; 1: CD000137.Google Scholar
David, AL, Thornton, S, Sutcliffe, A, Williams, P. (2015). Developing New Pharmaceutical Treatments for Obstetric Conditions. Royal College of Obstetricians & Gynaecologists. www.rcog.org.uk/globalassets/documents/guidelines/scientific-impact-papers/sip-50.pdfGoogle Scholar
Learmont, JG, Poston, L. Nitric oxide is involved in flow-induced dilation of isolated human small fetoplacental arteries. Am J Obstet Gynecol. 1996; 174: 583–8.Google Scholar
Duvekot, JJ, Cheriex, EC, Pieters, FAA, Menheere, PPCA, Schouten, HJA, Peeters, LLH. Maternal volume homeostasis in early pregnancy in relation to fetal growth restriction. Obstet Gynecol. 1995; 85: 361–7.Google Scholar
Duvekot, JJ, Cheriex, EC, Pieters, FA, Peeters, LL. Severely impaired fetal growth is preceded by maternal hemodynamic maladaptation in very early pregnancy. Acta Obstet Gynecol Scand. 1995; 74: 693–7.Google Scholar
Krause, BJ, Carrasco-Wong, I, Caniuguir, A, Carvajal, J, Farías, M, Casanello, P. Endothelial eNOS/arginase imbalance contributes to vascular dysfunction in IUGR umbilical and placental vessels. Placenta. 2013; 34: 20–8.Google Scholar
Kulandavelu, S, Whiteley, KJ, Bainbridge, SA, Qu, D, Adamson, SL. Endothelial NO synthase augments fetoplacental blood flow, placental vascularization, and fetal growth in mice. Hypertension. 2013; 61: 259–66.Google Scholar
Kähler, C, Schleußner, E, Möller, A, Seewald, HJ. Nitric oxide donors: effects on fetoplacental blood flow. Eur J Obstet Gynecol Reprod Biol. 2004; 115: 10–14.Google Scholar
Meher, S, Duley, L. Nitric oxide for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007; 2: CD006490.Google Scholar
Tiralongo, G, Pisani, I, Vasapollo, B, Khalil, A, Thilaganathan, B, Valensise, H. Nitric oxide (NO) donors and haemodynamic changes in fetal growth restriction. Ultrasound Obstet Gynecol. 2018; 4: 514–18.Google Scholar
Ormesher, L, Myers, JE, Chmiel, C, Wareing, M, Greenwood, SL, Tropea, T, et al. Effects of dietary nitrate supplementation, from beetroot juice, on blood pressure in hypertensive pregnant women: a randomised, double-blind, placebo-controlled feasibility trial. Nitric Oxide. 2018; 80: 37–44.Google Scholar
Schleussner, E, Lehmann, T, Kähler, C, Schneider, U, Schlembach, D, Groten, T. Impact of the nitric oxide-donor pentaerythrityltetranitrate on perinatal outcome in risk pregnancies: a prospective, randomized, double-blinded trial. J Perinat Med. 2014; 42: 507–14.Google Scholar
Wareing, M, Myers, JE, O’Hara, M, Kenny, LC, Warren, AY, Taggart, MJ, et al. Effects of a phosphodiesterase-5 (PDE5) inhibitor on endothelium-dependent relaxation of myometrial small arteries. Am J Obstet Gynecol. 2004; 190: 1283–90.Google Scholar
Wareing, M, Myers, JE, O’Hara, M, Baker, PN. Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. J Clin Endocrinol Metab. 2005; 90: 2550–5.Google Scholar
Russo, FM, Conings, S, Allegaert, K, van Mieghem, T, Toelen, J, van Calsteren, K, et al. Sildenafil crosses the placenta at therapeutic levels in a dually perfused human cotyledon model. Am J Obstet Gynecol. 2018; 219: 619. e1-619. e10.Google Scholar
Walton, RB, Reed, LC, Estrada, SM, Schmiedecke, SS, Villazana-Kretzer, DL, Napolitano, PG, et al. Evaluation of sildenafil and tadalafil for reversing constriction of fetal arteries in a human placenta perfusion model. Hypertension. 2018; 72: 167–76.Google Scholar
Samangaya, RA, Mires, G, Shennan, A, Skillern, L, Howe, D, McLeod, A, et al. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy. 2009; 28: 369–82.Google Scholar
Oyston, C, Stanley, JL, Oliver, MH, Bloomfield, FH, Baker, PN. Maternal administration of sildenafil citrate alters fetal and placental growth and fetal-placental vascular resistance in the growth-restricted ovine fetus. Hypertension. 2016; 68: 760–7.Google Scholar
Miller, SL, Loose, JM, Jenkin, G, Wallace, EM. The effects of sildenafil citrate (Viagra) on uterine blood flow and well being in the intrauterine growth-restricted fetus. Am J Obstet Gynecol. 2009; 200: 102. e1–7.Google Scholar
Von Dadelszen, P, Dwinnell, S, Magee, LA, Carleton, BC, Gruslin, A, Lee, B, et al. Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG. 2011; 118: 624–8.Google Scholar
Adel El-Sayed, M, Abdel-Aty Saleh, S, Ahmed Maher, M, Khidre, AM. Utero-placental perfusion Doppler indices in growth restricted fetuses: effect of sildenafil citrate. J Matern Fetal Neonatal Med. 2018; 31: 1045–50.Google Scholar
Ganzevoort, W, Alfirevic, Z, von Dadelszen, P, Kenny, L, Papageorghiou, A, van Wassenaer-Leemhuis, A, et al. STRIDER: Sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction? A protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis. Syst Rev. 2014; 3: 23.Google Scholar
Pels, A, Kenny, LC, Alfirevic, Z, Baker, PN, von Dadelszen, P, Gluud, C, et al. STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials. BMC Pregnancy Childbirth. 2017; 17: 440.Google Scholar
Sharp, A, Cornforth, C, Jackson, R, Harrold, J, Turner, MA, Kenny, LC, et al. Maternal sildenafil for severe fetal growth restriction (STRIDER ): a multicentre, randomised, placebo-controlled, double-blind trial. Lancet Child Adolesc Health. 2018; 2: 93–102.Google Scholar
Groom, KM, Ganzevoort, W, Alfirevic, Z, Lim, K, Papageorghiou, AT. Clinicians should stop prescribing sildenafil for fetal growth restriction (FGR): comment from the STRIDER Consortium. Ultrasound Obstet Gynecol. 2018; 52: 295–6.Google Scholar
Tanaka, K, Tanaka, H, Maki, S, Kubo, M, Nii, M, Magawa, S, et al. Cardiac function and tadalafil used for treating fetal growth restriction in pregnant women without cardiovascular disease. J Matern Neonatal Med. 2018; 20: 1–3.Google Scholar
Kubo, M, Umekawa, T, Maekawa, Y, Tanaka, H, Nii, M, Murabayashi, N, et al. Retrospective study of tadalafil for fetal growth restriction: impact on maternal and perinatal outcomes. J Obstet Gynaecol Res. 2017; 43: 291–7.Google Scholar
Tanaka, H, Kubo, M, Nii, M, Maki, S, Umekawa, T, Ikeda, T. Treatment using tadalafil for severe pre-eclampsia with fetal growth restriction. J Obstet Gynaecol Res. 2017; 43: 1205–8.Google Scholar
Sakamoto, M, Osato, K, Kubo, M, Nii, M, Tanaka, H, Murabayashi, N, et al. Early-onset fetal growth restriction treated with the long-acting phosphodiesterase-5 inhibitor tadalafil: a case report. J Med Case Rep. 2016; 10: 1–5.Google Scholar
Kubo-Kaneda, M, Tanaka, H, Maki, S, Nii, M, Umekawa, T, Osato, K, et al. Placental growth factor as a predictor of the efficacy of tadalafil treatment for fetal growth restriction. J Matern Neonatal Med. 2018; 0: 1–4.Google Scholar
Belo, L, Caslake, M, Santos-Silva, A, Castro, EMB, Pereira-Leite, L, Quintanilha, A, et al. LDL size, total antioxidant status and oxidised LDL in normal human pregnancy: a longitudinal study. Atherosclerosis. 2004; 177: 391–9.Google Scholar
Bauer, AJ, Banek, CT, Needham, K, Gillham, H, Capoccia, S, Regal, JF, et al. Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension. Hypertension. 2013; 61: 1103–10.Google Scholar
Yang, M-Y, Diao, Z-Y, Wang, Z-Y, Yan, G-J, Zhao, G-F, Zheng, M-M, et al. Pravastatin alleviates lipopolysaccharide-induced placental TLR4 over-activation and promotes uterine arteriole remodeling without impairing fetal development of rats. J Biomed Res. 2018; 32: 288–97.Google Scholar
Ofori, B, Oraichi, D, Blais, L, Rey, E, Berard, A. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: a nested case-control study. Birth Defects Res B Dev Reprod Toxicol. 2006; 77: 268–79.Google Scholar
Kane, AD, Herrera, EA, Hansell, JA, Giussani, DA. Statin treatment depresses the fetal defence to acute hypoxia via increasing nitric oxide bioavailability. J Physiol. 2012; 590: 323–34.Google Scholar
Costantine, MM, Cleary, K. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol. 2013; 121: 349–53.Google Scholar
Lefkou, E, Mamopoulos, A, Dagklis, T, Vosnakis, C, Rousso, D, Girardi, G. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest. 2016; 126: 2933–40.Google Scholar
Kaitu’u-Lino, TJ, Brownfoot, FC, Beard, S, Cannon, P, Hastie, R, Nguyen, TV, et al. Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction – implications for treating preeclampsia. PLoS ONE. 2018; 13: 1–14.Google Scholar
Cluver, CA, Walker, SP, Mol, BW, Theron, GB, Hall, DR, Hiscock, R, et al. Double blind, randomised, placebo-controlled trial to evaluate the efficacy of esomeprazole to treat early onset pre-eclampsia (PIE Trial): a study protocol. BMJ Open. 2015; 5: e008211.Google Scholar
Wang, M-J, Cai, W-J, Li, N, Ding, Y-J, Chen, Y, Zhu, Y-C. The hydrogen sulfide donor NaHS promotes angiogenesis in a rat model of hind limb ischemia. Antioxid Redox Signal. 2010; 12: 1065–77.Google Scholar
Cindrova-Davies, T, Herrera, EA, Niu, Y, Kingdom, J, Giussani, DA, Burton, GJ. Reduced cystathionine γ-lyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: hydrogen sulfide as a placental vasodilator. Am J Pathol. 2013; 182: 1448–58.Google Scholar
Holwerda, KM, Burke, SD, Faas, MM, Zsengeller, Z, Stillman, IE, Kang, PM, et al. Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor. J Am Soc Nephrol. 2014; 25: 717–25.Google Scholar
Wang, Y, Walli, AK, Schulze, A, Blessing, F, Fraunberger, P, Thaler, C, et al. Heparin-mediated extracorporeal low density lipoprotein precipitation as a possible therapeutic approach in preeclampsia. Transfus Apher Sci. 2006; 35: 103–10.Google Scholar
David, AL, Torondel, B, Zachary, I, Wigley, V, Nader, KA, Mehta, V, et al. Local delivery of VEGF adenovirus to the uterine artery increases vasorelaxation and uterine blood flow in the pregnant sheep. Gene Ther. 2008; 15: 1344–50.Google Scholar
Mehta, V, Abi-Nader, K, Peebles, D, Benjamin, E, Wigley, V, Torondel, B, et al. Long-term increase in uterine blood flow is achieved by local overexpression of VEGF-A(165) in the uterine arteries of pregnant sheep. Gene Ther. 2012; 19: 925–35.Google Scholar
Carr, DJ, Aitken, RP, Milne, JS, Peebles, DM, Martin, JF, Zachary, IC, et al. Prenatal Ad.VEGF gene therapy – a promising new treatment for fetal growth restriction. Hum Gene Ther. 2011; 22: A128.Google Scholar
Carr, DJ, Wallace, JM, Aitken, R, Milne, JS, Martin, JF, Zachary, IZ, et al. Peri- and postnatal effects of prenatal adenoviral VEGF gene therapy in growth-restricted sheep. Biol Reprod. 2016; 94: 142.Google Scholar
Swanson, AM, Rossi, CA, Ofir, K, Mehta, V, Boyd, M, Barker, H, et al. Maternal therapy with Ad.VEGF-A165 increases fetal weight at term in a guinea pig model of fetal growth restriction. Hum Gene Ther. 2016; 27: 997–1007.Google Scholar
Vaughan, OR, Rossi, CA, Ginsberg, Y, White, A, Hristova, M, Sebire, NJ, et al. Perinatal and long-term effects of maternal uterine artery adenoviral VEGF-A165 gene therapy in the growth-restricted guinea pig fetus. Am J Physiol Regul Integr Comp Physiol. 2018; 315: R344–53.Google Scholar
David, AL. Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction. Placenta. 2017; 59 (Suppl. 1): S44–50.Google Scholar
Sheppard, M, Spencer, RN, Ashcroft, R, David, AL. Ethics and social acceptability of a proposed clinical trial using maternal gene therapy to treat severe early-onset fetal growth restriction. Ultrasound Obstet Gynecol. 2016; 47: 484–91.Google Scholar
Spencer, R, Ambler, G, Brodszki, J, Diemert, A, Figueras, F, Gratacós, E, et al. EVERREST prospective study: a 6-year prospective study to define the clinical and biological characteristics of pregnancies affected by severe early onset fetal growth restriction. BMC Pregnancy Childbirth. 2017; 17: 43.Google Scholar
Royal College of Obstetricians and Gynaecologists. (2007). The Role of Emergency and Elective Interventional Radiology in Postpartum Haemorrhage. www.rcog.org.uk/globalassets/documents/guidelines/goodpractice6roleemergency2007.pdf.Google Scholar
Camacho-Hübner, C, Woods, KA, Clark, AJL, Savage, MO. Insulin-like growth factor (IGF)-I gene deletion. Rev Endocr Metab Disord. 2002; 3: 357–61.Google Scholar
Jones, HN, Crombleholme, T, Habli, M. Adenoviral-mediated placental gene transfer of IGF-1 corrects placental insufficiency via enhanced placental glucose transport mechanisms. PLoS ONE. 2013; 8: e74632.Google Scholar
Harris, LK. Could peptide-decorated nanoparticles provide an improved approach for treating pregnancy complications? Nanomedicine. 2016; 11: 2235–8.Google Scholar
King, A, Ndifon, C, Lui, S, Widdows, K, Kotamraju, VR, Agemy, L, et al. Tumor-homing peptides as tools for targeted delivery of payloads to the placenta. Sci Adv. 2016; 2: e1600349.Google Scholar
Cureton, N, Korotkova, I, Baker, B, Greenwood, S, Wareing, M, Kotamraju, R, et al. Selective targeting of a novel vasodilator to the uterine vasculature to treat impaired uteroplacental perfusion in pregnancy. Theranostics. 2017; 7: 3715–31.Google Scholar
Phillips, TJ, Scott, H, Menassa, DA, Bignell, AL, Sood, A, Morton, JS, et al. Treating the placenta to prevent adverse effects of gestational hypoxia on fetal brain development. Sci Rep. 2017; 7: 9079.Google Scholar
Beards, F, Jones, LE, Charnock, J, Forbes, K, Harris, LK. Placental homing peptide-microRNA inhibitor conjugates for targeted enhancement of intrinsic placental growth signaling. Theranostics. 2017; 7: 2940–55.Google Scholar
Vasapollo, B, Lo Presti, D, Gagliardi, G, Farsetti, D, Tiralongo, GM, Pisani, I, et al. Restricted physical activity in pregnancy reduces maternal vascular resistance and improves fetal growth. Ultrasound Obstet Gynecol. 2018; 51: 672–6.Google Scholar
Renshall, LJ, Morgan, HL, Moens, H, Cansfield, D, Finn-Sell, SL, Tropea, T, et al. Melatonin increases fetal weight in wild-type mice but not in mouse models of fetal growth restriction. Front Physiol. 2018; 9: 1–11.Google Scholar
Castillo-Melendez, M, Yawno, T, Sutherland, A, Jenkin, G, Wallace, EM, Miller, SL. Effects of antenatal melatonin treatment on the cerebral vasculature in an ovine model of fetal growth restriction. Dev Neurosci. 2017; 39: 323–37.Google Scholar
Chang, EY, Barbosa, E, Paintlia, MK, Singh, A, Singh, I. The use of N-acetylcysteine for the prevention of hypertension in the reduced uterine perfusion pressure model for preeclampsia in Sprague-Dawley rats. Am J Obstet Gynecol. 2005; 193: 952–6.Google Scholar
Hashimoto, K, Pinkas, G, Evans, L, Liu, H, Al-Hasan, Y, Thompson, LP. Protective effect of N-acetylcysteine on liver damage during chronic intrauterine hypoxia in fetal guinea pig. Reprod Sci. 2012; 19: 1001–9.Google Scholar
Roes, EM, Raijmakers, MT, Boo, TM, de Zusterzeel, PL, Merkus, HM, Peters, WH, et al. Oral N-acetylcysteine administration does not stabilise the process of established severe preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2006; 127: 61–7.Google Scholar
LaRosa, DA, Ellery, SJ, Parkington, HC, Snow, RJ, Walker, DW, Dickinson, H. Maternal creatine supplementation during pregnancy prevents long-term changes in diaphragm muscle structure and function after birth asphyxia. Pediatr Res. 2016; 80: 852–60.Google Scholar
Dickinson, H, Davies-Tuck, M, Ellery, S, Grieger, J, Wallace, E, Snow, R, et al. Maternal creatine in pregnancy: a retrospective cohort study. BJOG. 2016; 123: 1830–8.Google Scholar
Dickinson, H, Bain, E, Wilkinson, D, Middleton, P, Crowther, CA, Walker, DW. Creatine for women in pregnancy for neuroprotection of the fetus. Cochrane Database Syst Rev. 2014; 12: CD010846.Google Scholar
Rodger, MA, Gris, JC, de Vries, JIP, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet. 2016; 388: 2629–41.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×